TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Segmental contrast density (CD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial opacification (AO) in vessels with stenoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for repeat scan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: total swallow durations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of swallows per tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preference for ODT preparation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC0-36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence rates of MACCE
Endpoint domain: Mortality/survival
Primary endpoint: PISF total nitrite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative risk of infection
Endpoint domain: Mortality/survival
Primary endpoint: relative risk of death
Endpoint domain: Mortality/survival
Primary endpoint: relative risk of death from infection
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy rate of TVS RT‐3D‐HyCoSy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Misdiagnosis rate of TVS RT‐3D‐HyCoSy
Endpoint domain: Adverse events/effects
Primary endpoint: Observed spectacle wear at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of buccal infiltration in producing anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of combined endpoint (death, amputation, new thromboembolic complications)
Endpoint domain: Mortality/survival
Primary endpoint: Increase in platelet count by >/=30% to >10(9)/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Activated partial thromboplastin time (aPTT) values 1.5 to 3.0 times baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TNF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: APACHE III score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant Murley scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of eating breakfast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Targeted anti-factor Xa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic recurrent VTEs
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of etoricoxib compared to celecoxib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of etoricoxib and celecoxib
Endpoint domain: Adverse events/effects
Primary endpoint: sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maternal self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total caloric intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knee-specific quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inotropic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma levels of cardiac troponin-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical resolution at end of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriologic response rates at end of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological response rates at end of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of EAC and/or BE
Endpoint domain: Mortality/survival
Primary endpoint: Combined clinical and endoscopic remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N1P1 response densities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total withdrawal score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lumen area change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: MAC-BAR of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Negative stress test rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Sandvik Severity Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein requirements in non-menstrual periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum S-COMT inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-OMD C(max) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levodopa C(max) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADMA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SDMA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: National Eye Institute Visual Function Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recurrent optic neuritis
Endpoint domain: Adverse events/effects
Primary endpoint: CR rate of primary nasopharyngeal tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of NK cell and T3, T4 in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of people engaging in recreational physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lung deposition relative to nominal dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: on-task behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: achievement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: local recurrence at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: Increased clot lysis at 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased fibrinogen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased rate of hemorrhagic events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in oxygenation (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: manual muscle testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of moderate to severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target vessel revascularization (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: %EHR‐RCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: %EHR‐Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bowel function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: hospitalization time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Acceptability of the estradiol gel TX 11323
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Long-term developmental and behavioral outcome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant satisfaction with the course
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retention of participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Questionnaire return rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: antibody titers >10 mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: technical success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: post-ERCP pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: incident cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: duration of oxygen therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Isoprostanes levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sputum negative conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacteriological relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: AF-related morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Self-reported falls
Endpoint domain: Adverse events/effects
Primary endpoint: Functional Gait Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of death or severe HIV-related illness
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of Alveolar Osteitis (AO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour volume changes after 14 days of neoadjuvant chemoradiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure Normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate Variability (HRV) Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Postprandial Hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SKAMP-Combined score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous abstinence rate from smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clearance of idraparinux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life of idraparinux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in agitation and aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical success (residual luminal narrowing < 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food label literacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: core stability measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the time‐concentration curve (AUC₀₋₃₆)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration 5 min before the end of infusion (C(ss))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distress during invasive procedures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cooperation during procedures
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Bronchodilator Response (BDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Live births after IVF/embryo transfer
Endpoint domain: Mortality/survival
Primary endpoint: postexercise blood lactate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post prandial blood glucose (PPBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pulse pressure (PP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate pressure product (RPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Double product (Do‐P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in mood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPT-free time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of SPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum neutrophil gelatinase‐associated lipocalin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 12-month overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Mean CMT decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent leakage rate
Endpoint domain: Adverse events/effects
Primary endpoint: Vmax and Km for p.o. and i.v. fomepizole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of p.o. fomepizole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T>MEC duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum TSH measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Median change in NfL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-density lipoprotein (LDL) cholesterol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Regression of thoracic aortic plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Progression of abdominal aortic plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: inflammatory lesion count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 2 or higher IGA improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of protective feeding practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma uric acid response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to plasma uric acid control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normal slow-wave percentage after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of willingness to quit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative aqueous flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: white matter hyperintensities volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of lacunes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Non-inferiority of the intradermal vaccine for A/H1N1 and B strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of injection-site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Bacterial cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mental development index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of death, reinfarction, disabling stroke, and ischemia-driven revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Overall physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction with physician's care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall health status improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: articulatory accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: frequency of eye injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation difficulty score (IDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total duration for intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: muscle strength in upper limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical mortality
Endpoint domain: Mortality/survival
Primary endpoint: Major morbidity rate
Endpoint domain: Adverse events/effects
Primary endpoint: End Treatment Response (ETR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall cure rate of MRSA infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clear to almost clear outcome at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximal knee extensor angular velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal knee extensor power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality within 30 days of surgery
Endpoint domain: Mortality/survival
Primary endpoint: Fractional Synthesis Rate (FSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional Breakdown Rate (FBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hb A1C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Degree of pulmonary damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensory duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate within 45 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Hb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of malaria infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Iron deficiency prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of recorded visits per year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to Active-online
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeated participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cervical length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transverse diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diameter of the internal os
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25(OH)D3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NfL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasopressor requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea during the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of perioperative myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of intensive care unit stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean received tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for modified BVM
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean slope of vitamin D3 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse reactions (bone marrow suppression, mucositis, diarrhea)
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of acute cellular rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of gout
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes